Sunesis reports SNS-595 shows activity against tumors, is well tolerated

New York, June 6 - Sunesis Pharmaceuticals, Inc. presented data from two phase 1 studies of SNS-595 showing that the drug exhibited clinical activity across a variety of tumor types among end-stage refractory patient populations and was well-tolerated with manageable side effects.

The trials evaluated once-weekly and once-every-three-week dosing schedules in patients with advanced solid malignancies.

Out of a total of 62 patients that could be evaluated from the two studies, two achieved partial responses, 17 patients achieved stable disease for 15 weeks or greater, with one patient maintaining stable disease for more than a year.

Patients enrolled in both studies had advanced disease in a variety of tumor types including ovarian, lung, colon, pancreatic and renal. All had previously progressive disease at the time of enrollment despite prior treatments.

"SNS-595 appears to possess several compelling attributes. SNS-595 has been well tolerated to date, can be dosed on convenient dosing schedules, and has shown evidence of clinical activity across multiple tumor types," Herbert Hurwitz, associate professor of medical oncology and transplantation at Duke University, said in a news release.

The findings were presented at the American Society of Clinical Oncology Meeting annual meeting.

Sunesis, a South San Francisco, Calif., clinical-stage biopharmaceutical company, said it is currently conduction phase 2 clinical studies of SNS-595 in non-small cell and small-cell lung cancers, with another study being planned for patients with ovarian cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.